Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Develop Gene-Based Theranostic for ARCA Heart Failure Drug

NEW YORK (GenomeWeb News) — Laboratory Corporation of America today said it plans to develop a gene-based companion diagnostic to be paired with a cardiac drug ARCA Discovery is currently developing, the companies said today.
The test will identify genetic variations of the alpha-2c and the beta-1 adrenergic receptors, which appear to affect the way heart failure patients respond to the ARCA drug bucindolol.
Some variations of the receptors are associated with positive benefits in many patients, but other variants are associated with side effects, the companies said.
ARCA intends to seek approval for the drug along with the genetic test, which LabCorp will develop during the approval process.
Financial terms of the agreement were not released.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.